June 24, 2025 – Talk Bio

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

7 days ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

7 days ago talkbio0Tagged deceptive marketing, Glucagon-Like Peptide 1, Hims & Hers, Nordisk, partnership termination, stock plunge, Telemedicine, Wegovy, Weight-Loss Agents

Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs

FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover

7 days ago talkbio0Tagged agency departures, CDER, Drug Regulations, Jacqueline Corrigan-Curay, Leadership, Personnel Turnover, Retirement, United States Food and Drug Administration

FDA; Jacqueline Corrigan-Curay; CDER; retirement; leadership turnover; drug regulation; agency departures

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

7 days ago talkbio0Tagged ACIP, Advisory Committees, Bill Cassidy, Centers for Disease Control and Prevention (U.S.), Confirmation, Deferred, HELP Committee, Policy, RFK Jr., Senate, Vaccines

Bill Cassidy; RFK Jr.; CDC; vaccine advisory committee; ACIP; confirmation; deferral; Senate HELP Committee; vaccine policy

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

7 days ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

7 days ago talkbio0Tagged Clinical Development, daraxonrasib, Neoplasms, Pharma, RAS, RAS cancer, Revolution Medicines, Royalty, secured debt, synthetic royalty

Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding

Sanofi Licenses Formation Bio’s JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

7 days ago talkbio0Tagged AI drug development, Anabolism, Bio, chronic hand eczema, gusacitinib, Indication of (contextual qualifier), JAK/SYK inhibitor, Libertas Bio, licensing agreement, sanofi

Sanofi; Formation Bio; gusacitinib; JAK/SYK inhibitor; AI drug development; Libertas Bio; deal; chronic hand eczema; new indication; licensing agreement

Illumina Acquires SomaLogic to Accelerate Proteomics Strategy with $350M Upfront

7 days ago talkbio0Tagged Acquisition, Biotechnology, Illumina, Proteomics, SomaLogic, Standard BioTools

Illumina; SomaLogic; Standard BioTools; proteomics; acquisition; biotechnology

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

1 week ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial